Reata Pharmaceuticals, Inc.

Period: 10/15/2019 to 08/07/2020
Lead Plaintiff Deadline: 12/14/2020


A securities class action has been filed against Reata Pharmaceuticals, Inc. (RETA) on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired Reata securities between October 15, 2019 through August 7, 2020.  This case has been filed in the USDC – E.D.TX.

Reata was founded in 2002 and is headquartered in Plano, Texas.  The Company was formerly known as Reata Discovery, Inc., and changed its name to Reata Pharmaceuticals, Inc. in May 2005.   Reata is a clinical stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.

Among Reata’s drug candidates under development is omaveloxolone, which is in Phase 2 clinical development to treat Friedreich’s ataxia (“FA”). Following the announcement of positive data from the MOXIe Part 2 study of omaveloxolone for FA in October 2019, the Company represented that it would seek submission for marketing approval of omaveloxolone for the treatment of FA in the U.S. with the U.S. Food and Drug Administration (“FDA”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the MOXIe Part 2  study  results  were  insufficient  to  support  a  single  study  marketing  approval  of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.